Tagged Content

Year: Medication:  Abilify (aripiprazole) Addyi Antipsychotics Aripiprazole Aristada Belsomra Brintellix Buprenorphine and naloxone Probuphine Clozapine Clozapine REMS Chantix and Zyban Cymbalta Daytrana Diazepam Effexor Farxiga Fentanyl and Opioids Geodon Hysingla ER Ingrezza Lamictal (lamotrigine) Lorazepam Lucemyra (lofexidine hydrochloride) Lunesta Methylphenidate Naloxone Naloxone/Evzio Naltrexone Olanzapine Olanzapine/Zyprexa Opana ER Opioids UPDATE: Opioids Opioids and Benzodiazepines UPDATE: Opioids and Benzodiazepines Rexulti Spravato (Esketamine) Strattera Sublocade Tanzeum Targiniq ER Tramadol Treatment for Alcohol Use Disorder Vraylar Vynase Ziprasidone Zolpidem Zyprexa   General Resources:   DEA Pharmacists' Manual FDA Medication Updates NIMH Mental Health Medications Guide     2019   FDA releases updated Drug Safety Communication about Opioids The update reinforces that individuals who are physically dependent on opioids may experience serious harm if their medications are suddenly discontinued or their dose is rapidly decreased. Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program Modified The FDA has approved a modification to the REMS program that implements new requirements for prescribers in February 2019. FDA approves Spravato (esketamine) for treatment-resistant depression The U.